Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 1 , Pages 51-63 , February 2009

The role of the endocannabinoid system in lipogenesis and fatty acid metabolism

References 

  1. Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature. Apr 12 2001;410(6830):822–825
  2. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. Dec 18 1992;258(5090):1946–1949
  3. Pagotto U, Marsicano G, Cota D, et al. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocrine Reviews. Feb 2006;27(1):73–100
  4. Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. Aug 9 1990;346(6284):561–564
  5. O'Sullivan SE. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. British Journal of Pharmacology. Nov 2007;152(5):576–582
  6. Pagano C, Pilon C, Calcagno A, et al. The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. The Journal of Clinical Endocrinology and Metabolism. Dec 2007;92(12):4810–4819
  7. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. The Journal of Clinical Investigation. May 2005;115(5):1298–1305
  8. Bluher M, Michael MD, Peroni OD, et al. Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Developmental Cell. Jul 2002;3(1):25–38
  9. Cota D, Marsicano G, Tschop M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. The Journal of Clinical Investigation. Aug 2003;112(3):423–431
  10. Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. Apr 16–22 2005;365(9468):1389–1397
  11. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA: the Journal of the American Medical Association. Feb 15 2006;295(7):761–775
  12. Scheen AJ, Finer N, Hollander P, et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet. Nov 11 2006;368(9548):1660–1672
  13. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. The New England Journal of Medicine. Nov 17 2005;353(20):2121–2134
  14. Matias I, Gonthier MP, Orlando P, et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. The Journal of Clinical Endocrinology and Metabolism. Aug 2006;91(8):3171–3180
  15. Bensaid M, Gary-Bobo M, Esclangon A, et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Molecular Pharmacology. Apr 2003;63(4):908–914
  16. Hildebrandt AL, Kelly-Sullivan DM, Black SC. Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice. European Journal of Pharmacology. Feb 21 2003;462(1–3):125–132
  17. Roche R, Hoareau L, Bes-Houtmann S, et al. Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes. Histochemistry and Cell Biology. Aug 2006;126(2):177–187
  18. Spoto B, Fezza F, Parlongo G, et al. Human adipose tissue binds and metabolizes the endocannabinoids anandamide and 2-arachidonoylglycerol. Biochimie. Dec 2006;88(12):1889–1897
  19. Bluher M, Engeli S, Kloting N, et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes. Nov 2006;55(11):3053–3060
  20. Ravinet Trillou C, Delgorge C, Menet C, et al. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. International Journal of Obesity and Related Metabolic Disorders. Apr 2004;28(4):640–648
  21. Ravinet Trillou C, Arnone M, Delgorge C, et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. American Journal of Physiology Regulatory Integrative and Comparative Physiology. Feb 2003;284(2):R345–R353
  22. Jbilo O, Ravinet-Trillou C, Arnone M, et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. The FASEB Journal. Sep 2005;19(11):1567–1569
  23. Herling AW, Kilp S, Elvert R, et al. Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats. Endocrinology. May 2008;149(5):2557–2566
  24. Wilson-Fritch L, Nicoloro S, Chouinard M, et al. Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. The Journal of Clinical Investigation. Nov 2004;114(9):1281–1289
  25. Bogacka I, Ukropcova B, McNeil M, et al. Structural and functional consequences of mitochondrial biogenesis in human adipocytes in vitro. The Journal of Clinical Endocrinology and Metabolism. Dec 2005;90(12):6650–6656
  26. Bogacka I, Xie H, Bray GA, et al. Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. Diabetes. May 2005;54(5):1392–1399
  27. Tedesco L, Valerio A, Cervino C, et al. Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes. Diabetes. Aug 2008;57(8):2028–2036
  28. Handschin C, Spiegelman BM. Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocrine Reviews. Dec 2006;27(7):728–735
  29. Bartova A, Birmingham MK. Effect of delta9-tetrahydrocannabinol on mitochondrial NADH-oxidase activity. The Journal of Biological Chemistry. Aug 25 1976;251(16):5002–5006
  30. Gonthier MP, Hoareau L, Festy F, et al. Identification of endocannabinoids and related compounds in human fat cells. Obesity (Silver Spring, Md.). Apr 2007;15(4):837–845
  31. Engeli S, Bohnke J, Feldpausch M, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes. Oct 2005;54(10):2838–2843
  32. Nisoli E, Clementi E, Paolucci C, et al. Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science. Feb 7 2003;299(5608):896–899
  33. Nisoli E, Tonello C, Cardile A, et al. Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS. Science. Oct 14 2005;310(5746):314–317
  34. Gasperi V, Fezza F, Pasquariello N, et al. Endocannabinoids in adipocytes during differentiation and their role in glucose uptake. Cellular and Molecular Life Sciences. Jan 2007;64(2):219–229
  35. Kola B, Hubina E, Tucci SA, et al. Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. The Journal of Biological Chemistry. Jul 1 2005;280(26):25196–25201
  36. Buettner C, Muse ED, Cheng A, et al. Leptin controls adipose tissue lipogenesis via central, STAT3-independent mechanisms. Nature Medicine. Jun 2008;14(6):667–675
  37. Liu YL, Connoley IP, Wilson CA, et al. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. International Journal of Obesity. Feb 2005;29(2):183–187
  38. Lofgren P, Sjolin E, Wahlen K, et al. Human adipose tissue cannabinoid receptor 1 gene expression is not related to fat cell function or adiponectin level. The Journal of Clinical Endocrinology and Metabolism. Apr 2007;92(4):1555–1559
  39. Kempf K, Hector J, Strate T, et al. Immune-mediated activation of the endocannabinoid system in visceral adipose tissue in obesity. Hormone and Metabolic Research. Aug 2007;39(8):596–600
  40. Ferre P. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes. Feb 2004;53(Suppl. 1):S43–S50
  41. Stienstra R, Duval C, Muller M, et al. PPARs, Obesity, and Inflammation. PPAR Research. 2007;2007:95974
  42. Moreno S, Farioli-Vecchioli S, Ceru MP. Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience. 2004;123(1):131–145
  43. Cimini A, Benedetti E, Cristiano L, et al. Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons. Neuroscience. 2005;130(2):325–337
  44. Sun Y, Alexander SP, Kendall DA, et al. Cannabinoids and PPARalpha signalling. Biochemical Society Transactions. Dec 2006;34(Pt 6):1095–1097
  45. Kozak KR, Gupta RA, Moody JS, et al. 15-Lipoxygenase metabolism of 2-arachidonylglycerol. Generation of a peroxisome proliferator-activated receptor alpha agonist. The Journal of Biological Chemistry. Jun 28 2002;277(26):23278–23286
  46. Liu J, Li H, Burstein SH, et al. Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid. Molecular Pharmacology. May 2003;63(5):983–992
  47. Rockwell CE, Snider NT, Thompson JT, et al. Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2. Molecular Pharmacology. Jul 2006;70(1):101–111
  48. O'Sullivan SE, Tarling EJ, Bennett AJ, et al. Novel time-dependent vascular actions of Delta9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma. Biochemical and Biophysical Research Communications. Nov 25 2005;337(3):824–831
  49. Bouaboula M, Hilairet S, Marchand J, et al. Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. European Journal of Pharmacology. Jul 11 2005;517(3):174–181
  50. Kliewer SA, Sundseth SS, Jones SA, et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proceedings of the National Academy of Sciences of the United States of America. Apr 29 1997;94(9):4318–4323
  51. Matias I, Petrosino S, Racioppi A, et al. Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: effect of high fat diets. Molecular and Cellular Endocrinology. Apr 16 2008;286(1–2 Suppl. 1):S66–S78
  52. Fu J, Gaetani S, Oveisi F, et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature. Sep 4 2003;425(6953):90–93
  53. Guzman M, Lo Verme J, Fu J, et al. Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha). The Journal of Biological Chemistry. Jul 2 2004;279(27):27849–27854
  54. LoVerme J, Russo R, La Rana G, et al. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. The Journal of Pharmacology and Experimental Therapeutics. Dec 2006;319(3):1051–1061
  55. Barish GD, Narkar VA, Evans RM. PPAR delta: a dagger in the heart of the metabolic syndrome. The Journal of Clinical Investigation. Mar 2006;116(3):590–597
  56. Yan ZC, Liu DY, Zhang LL, et al. Exercise reduces adipose tissue via cannabinoid receptor type 1 which is regulated by peroxisome proliferator-activated receptor-delta. Biochemical and Biophysical Research Communications. Mar 9 2007;354(2):427–433
  57. D'Eon TM, Pierce KA, Roix JJ, et al. The role of adipocyte insulin resistance in the pathogenesis of obesity-related elevations in endocannabinoids. Diabetes. May 2008;57(5):1262–1268
  58. Murdolo G, Kempf K, Hammarstedt A, et al. Insulin differentially modulates the peripheral endocannabinoid system in human subcutaneous abdominal adipose tissue from lean and obese individuals. Journal of Endocrinological Investigation. Sep 2007;30(8):RC17–RC21
  59. Starowicz KM, Cristino L, Matias I, et al. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity (Silver Spring, Md.). Mar 2008;16(3):553–565
  60. Monteleone P, Matias I, Martiadis V, et al. Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology. Jun 2005;30(6):1216–1221
  61. Cote M, Matias I, Lemieux I, et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. International Journal of Obesity. Apr 2007;31(4):692–699
  62. Di Marzo V. The endocannabinoid system in obesity and type 2 diabetes. Diabetologia. Aug 2008;51(8):1356–1367
  63. Pagano C, Rossato M, Vettor R. Endocannabinoids, adipose tissue and lipid metabolism. Journal of Neuroendocrinology. May 2008;20(Suppl. 1):124–129
  64. Pocai A, Obici S, Schwartz GJ, et al. A brain-liver circuit regulates glucose homeostasis. Cell Metabolism. Jan 2005;1(1):53–61
  65. Buettner C, Pocai A, Muse ED, et al. Critical role of STAT3 in leptin's metabolic actions. Cell Metabolism. Jul 2006;4(1):49–60
  66. Asilmaz E, Cohen P, Miyazaki M, et al. Site and mechanism of leptin action in a rodent form of congenital lipodystrophy. The Journal of Clinical Investigation. Feb 2004;113(3):414–424
  67. Uno K, Katagiri H, Yamada T, et al. Neuronal pathway from the liver modulates energy expenditure and systemic insulin sensitivity. Science. Jun 16 2006;312(5780):1656–1659
  68. Osei-Hyiaman D, Liu J, Zhou L, et al. Hepatic CB(1) receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. The Journal of Clinical Investigation. Aug 1 2008;
  69. Pavon FJ, Serrano A, Perez-Valero V, et al. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats. Journal of Neuroendocrinology. May 2008;20(Suppl. 1):116–123
  70. Chen RZ, Frassetto A, Lao JZ, et al. Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabinoid CB1 receptor. European Journal of Pharmacology. Apr 28 2008;584(2–3):338–342
  71. Nissen SE, Nicholls SJ, Wolski K, et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA: the Journal of the American Medical Association. Apr 2 2008;299(13):1547–1560

PII: S1521-690X(08)00120-6

doi: 10.1016/j.beem.2008.10.002

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 1 , Pages 51-63 , February 2009

Article Tools

* Image Usage & Resolution